AbbVie sponsored the study. Dr. Poordad has received research support and acted as a consultant to the company. He also disclosed receiving grants or research support or acting as an adviser or speaker for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, in addition to others.
Conference Coverage
All-oral, triple-acting HCV regimen cures more than 90% of cirrhotic cases
